Zydus Lifesciences Receives USFDA Nod For Generic Gabapentin Tablets
According to the reports in the media, Zydus Lifesciences, a pharmaceutical company, has secured approval from the US Food and Drug Administration (USFDA) to market a generic medication for postherpetic neuralgia. The company received final approval for manufacturing and marketing Gabapentin tablets in 300 mg and 600 mg strengths, making it the first to receive such approval.
The product, with annual sales of USD 85 million in the US, will be launched promptly in the US market. Reportedly, Zydus shares were trading down 2.27 per cent at Rs 735.30 apiece on the BSE.
